Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

A review of 32 years of global data on FSGS highlights increased prevalence, with a limitation of biopsy variation and regional practices.


Global Data Suggest Increased Prevalence of Focal Segmental Glomerulosclerosis

A curated recap of 8 impactful trial updates from the American Society of Nephrology Kidney Week 2025.

Kidney Week 2025 Recap: 8 Trial Updates to Know in Nephrology

Sparsentan shows superior proteinuria reduction in pediatric FSGS patients, setting the stage for potential FDA approval.

Understanding Sparsentan in Pediatric FSGS, With Michelle Rheault, MD

New findings reveal sparsentan significantly reduces proteinuria in FSGS patients, offering hope for improved kidney health and lower failure risk.

DUPLEX: Sparsentan Outperforms Irbesartan in Reaching Key Proteinuria Threshold in FSGS

Kidney Week 2025 showcases groundbreaking clinical trials and FDA approvals, marking a transformative era in nephrology and kidney disease treatment.

ASN Kidney Week 2025 Preview: 5 Phase 3 Trials to Know

The Q3 recap for nephrology spotlights key FDA decisions, new KDIGO IgA nephropathy guidelines, and other top renal news and research.

Q3 2025 Recap: Nephrology News and Updates

An audio recap of the top 5 stories in healthcare news from the week of 9/5-9/13.

HCPLive 5 Stories in Under 5: Week of 09/07

Upon further review of the sNDA, the Agency indicated an advisory committee for sparsentan in FSGS is no longer needed. 

FDA Removes Sparsentan (Filspari) Advisory Committee Meeting for FSGS sNDA

The Q2 recap for nephrology spotlights key FDA decisions and top coverage from the 62nd European Renal Association Congress.

Q2 2025 Recap: Nephrology News and Updates

A study presented at ERA 2025 validates the use of proteinuria as a surrogate endpoint for FSGS clinical trials. 

RaDaR Validation Confirms PARASOL Findings on FSGS Surrogate Endpoint, with Daniel Gale, PhD, MB BChir

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 